Owens & Minor (NYSE:OMI) Issues FY 2024 Earnings Guidance

Owens & Minor (NYSE:OMI) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of 1.500-1.530 for the period, compared to the consensus earnings per share estimate of 1.510. The company issued revenue guidance of $10.7 billion-$10.7 billion, compared to the consensus revenue estimate of $10.7 billion. Owens & Minor also updated its Q4 2024 guidance to 0.520-0.550 EPS.

Owens & Minor Stock Performance

NYSE OMI traded down $4.01 on Monday, hitting $10.23. 1,504,415 shares of the stock traded hands, compared to its average volume of 546,443. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.45 and a current ratio of 1.09. The business’s fifty day moving average is $13.86 and its two-hundred day moving average is $14.32. Owens & Minor has a 12 month low of $10.54 and a 12 month high of $28.35. The firm has a market capitalization of $788.53 million, a price-to-earnings ratio of -15.73, a PEG ratio of 0.40 and a beta of 0.48.

Owens & Minor (NYSE:OMI) last posted its earnings results on Monday, November 4th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. The business had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.68 billion. During the same quarter in the previous year, the firm earned $0.44 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. As a group, equities analysts anticipate that Owens & Minor will post 1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on OMI shares. Robert W. Baird cut their price target on shares of Owens & Minor from $19.00 to $14.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Citigroup cut their target price on Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. UBS Group dropped their price objective on Owens & Minor from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. Finally, Barclays cut their target price on shares of Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.50.

Insider Buying and Selling at Owens & Minor

In related news, CFO Jonathan A. Leon sold 5,282 shares of Owens & Minor stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $11.82, for a total transaction of $62,433.24. Following the completion of the sale, the chief financial officer now owns 130,822 shares in the company, valued at $1,546,316.04. This trade represents a 3.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.62% of the company’s stock.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.